Laser Assisted Hatching — Cost, Top Hospitals & Success Rates | MyMedicPlus

Laser assisted hatching (LAH) is a specialised embryology technique performed in an in vitro fertilisation (IVF) laboratory, in which a precision infrared diode laser is used to create a small opening or thinning in the zona pellucida — the glycoprotein outer shell that surrounds a human embryo. The goal is to facilitate the natural process of hatching, in which the developing blastocyst must break free of the zona pellucida before it can implant into the uterine wall.

Under normal circumstances, an embryo hatches from its zona pellucida on Day 5–6 of development through a combination of enzymatic activity, expanding blastocyst pressure, and uterine secretions. In some patients, however, the zona pellucida is unusually thick, hardened, or dysmorphic — a condition that may physically impede hatching and prevent successful implantation. LAH is designed to overcome this barrier.

First described by Jacques Cohen and colleagues in 1992, assisted hatching initially used acidified Tyrode's solution (chemical hatching) or mechanical needles (mechanical hatching) to breach the zona. Laser hatching, introduced in the late 1990s, is now the preferred technique because of its precision, speed, reproducibility, and lower risk of embryo damage compared to chemical or mechanical methods.

The procedure adds minimal time to the IVF cycle (under one minute per embryo) and is performed on the morning of embryo transfer. It is not a treatment in itself but an adjunct to standard IVF or ICSI (intracytoplasmic sperm injection) protocols.

Laser assisted hatching is not recommended for all IVF patients. Evidence-based guidelines from the American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE) support its use in the following clinical scenarios:

• Recurrent IVF failure: Patients who have undergone 2 or more IVF cycles with good-quality embryos but failed to achieve implantation are the most established candidates for LAH. This is the scenario with the strongest evidence for benefit.
• Advanced maternal age (typically ≥37 years): Older eggs tend to produce embryos with thicker, harder zona pellucida. LAH may improve hatching success in this population.
• Elevated day-3 FSH: A marker of diminished ovarian reserve; associated with poorer embryo quality and zona abnormalities.
• Thick or dysmorphic zona pellucida: Embryologists may observe an unusually thick zona (>15 µm) or irregular zona morphology during embryo grading; these embryos are selected for LAH on a case-by-case basis.
• Cryopreserved (frozen) embryo transfers: The freeze-thaw process can harden the zona pellucida. LAH before frozen embryo transfer (FET) is practised in many clinics to compensate for this effect.
• Poor embryo grading: Grade 3 or 4 embryos (with significant fragmentation) that nevertheless have adequate cell number may benefit from LAH as an additional supportive measure.

LAH is generally not recommended for patients in their first IVF cycle with good-quality embryos and no prior failure, as studies have not shown consistent benefit in this group and there is a small risk of identical twinning.

The decision to use laser assisted hatching is made jointly by the reproductive endocrinologist and the embryology team, based on a review of the patient's history and real-time embryo assessment on the day of transfer:

Ideal Candidates

• Women ≥37 years with any number of IVF cycles, or younger women with ≥2 failed IVF cycles with good-quality embryos
• Couples with frozen embryos showing post-thaw zona hardening
• Day-3 FSH level above 10–12 IU/L
• Embryologist observation of zona pellucida thickness above 15 µm on routine grading
• Embryos with fragmentation ≥25% that are still being considered for transfer

Absolute Requirement

The LAH must be performed by a trained embryologist with access to a calibrated inverted microscope equipped with an infrared diode laser micromanipulation system (e.g., Saturn Active laser by RI, or ZILOS-tk system). The procedure cannot be performed without specialised laboratory equipment.

When LAH Is Not Recommended

• First IVF cycle in a young woman (<35) with normal embryo quality — evidence does not support routine use
• Poor ovarian response with very few embryos where any additional risk of embryo damage is unacceptable
• Patients with genetically tested (PGT-A) euploid embryos — zona thinning occurs naturally with the biopsy hole already present

Laser assisted hatching is performed in the IVF embryology laboratory on the morning of embryo transfer (usually Day 3 or Day 5 of development). The patient does not participate directly in this step — it is performed entirely on the embryo in a controlled laboratory environment.

Step-by-Step Procedure

1. Embryo preparation: The selected embryo(s) are placed in a temperature-controlled dish containing culture medium under the stage of an inverted microscope. The embryologist selects the best embryo(s) based on morphological grading (cell number, symmetry, fragmentation).
2. Zona pellucida visualisation: The inverted microscope provides magnification of 200–400×. The embryologist identifies the thickest portion of the zona pellucida, typically adjacent to the perivitelline space (away from the inner cell mass or blastomeres).
3. Laser application: The infrared diode laser (1,480 nm wavelength) is fired in brief pulses of 1–5 milliseconds. The laser energy is absorbed by the water in the zona pellucida, creating a precise, controlled opening of 20–40 µm — approximately one-quarter of the zona's circumference. Most modern systems require 2–5 laser pulses to create the opening.
4. Quality check: The embryologist confirms that the laser has created a clean, adequate opening without damage to the blastomeres. The embryo is inspected under the microscope for 2–5 minutes.
5. Return to culture / embryo transfer: The embryo is returned to the incubator briefly or taken directly to the transfer procedure, which is performed by the reproductive endocrinologist using a transcervical embryo transfer catheter.

Comparison with Other Hatching Methods

• Chemical hatching (Tyrode's acid): Acidified solution dissolves the zona; less precise and carries higher risk of blastomere damage from acid exposure. Now rarely used.
• Mechanical hatching (partial zona dissection): A microneedle is used to pierce and scratch the zona; technically demanding and inconsistent. Largely replaced by laser.
• Laser hatching: Most precise, reproducible, and safe of the three methods; the current standard of care when assisted hatching is indicated.

When applied to the right patient population, laser assisted hatching offers several advantages:

• Improved implantation in selected patients: Meta-analyses report a 5–15% absolute improvement in clinical pregnancy rates in patients with previous IVF failures, with the benefit most pronounced in those with 2 or more prior failed cycles.
• Precision and safety: The infrared diode laser creates a highly controlled, reproducible opening with minimal heat spread, reducing the risk of cellular damage compared to earlier chemical or mechanical methods.
• Speed: The entire LAH procedure takes under one minute per embryo, adding negligible time to the embryo transfer workflow.
• No patient discomfort: Unlike most medical procedures, LAH involves no patient preparation, anaesthesia, or recovery — it is performed entirely on the embryo outside the body.
• May benefit frozen embryo transfers: Post-thaw zona hardening is a recognised phenomenon; LAH before frozen embryo transfer may partially restore natural hatching capability.
• Low additional cost: Relative to the total cost of an IVF cycle, the additional cost of LAH ($200–$600) is modest if it increases the chance of a successful pregnancy in poor-prognosis patients.
• No increase in birth defects: Long-term follow-up studies have not found elevated rates of congenital anomalies in children born after laser assisted hatching.

Laser assisted hatching is considered safe, but patients should be aware of its limitations and potential downsides:

Technical Risks

• Embryo damage: Incorrect laser targeting or excessive pulse energy can damage blastomeres adjacent to the zona, potentially reducing embryo viability. This risk is virtually eliminated at clinics with experienced embryologists and calibrated laser systems.
• Incomplete opening: A hole that is too small may not adequately facilitate hatching; one that is too large may allow cells to extrude abnormally.

Clinical Risks

• Increased monozygotic twinning: The most consistently reported risk; the zona opening may allow the inner cell mass to split. The rate of identical twins after assisted hatching is approximately 1–2% above the already elevated IVF baseline rate (0.5–1%). Multiple pregnancy carries substantial maternal and neonatal risks including preterm birth, low birth weight, and preeclampsia.
• No proven benefit in unselected populations: Routine use of LAH in all IVF patients is not supported by evidence. Applying it indiscriminately may add cost and a small theoretical risk without measurable benefit.

Psychosocial Considerations

• LAH can raise unrealistic expectations. Patients must understand that even with LAH, IVF success rates are primarily determined by embryo chromosomal quality, uterine receptivity, and endometrial factors — not zona thickness alone.
• A failed cycle after LAH should be evaluated comprehensively rather than repeating LAH without investigating other factors.

Because LAH is a laboratory procedure performed on the embryo rather than the patient, there is no specific recovery related to the hatching step itself. The overall IVF recovery and follow-up protocol applies:

After Embryo Transfer (Day of Transfer)

Patients are advised to rest for 15–30 minutes after transcervical embryo transfer. Most clinics allow return to normal light activities the same day. Heavy lifting, vigorous exercise, and sexual intercourse are usually avoided for 48–72 hours.

Luteal Phase Support

Progesterone supplementation (vaginal pessaries, injections, or oral) is prescribed to support the uterine lining for implantation, typically continuing until 8–12 weeks of pregnancy if the cycle is successful.

Pregnancy Test

A blood beta-hCG pregnancy test is performed 10–14 days after embryo transfer. A positive result is followed by serial hCG measurements and a transvaginal ultrasound at 6–7 weeks to confirm intrauterine pregnancy, fetal heartbeat, and number of gestational sacs (important when LAH-related monozygotic twinning is a concern).

If the Cycle Fails

A failed cycle review appointment should assess embryo quality, endometrial receptivity (thickness, pattern), and immunological or anatomical factors. Recurrent implantation failure (3+ failed transfers of good-quality embryos) warrants a specialist evaluation including ERA (endometrial receptivity array), PGT-A (preimplantation genetic testing), thrombophilia screening, and immunological assessment.

LAH is an add-on to a standard IVF cycle. The additional cost for LAH itself is modest relative to the total IVF investment:

Key Cost Drivers

• Laboratory equipment: Clinics with state-of-the-art diode laser systems (RI Saturn, Hamilton Thorne ZILOS-tk) may charge slightly more for LAH reflecting capital equipment costs.
• Embryologist expertise: Clinics with dedicated micromanipulation embryologists may price LAH as a premium service.
• Package inclusions: Some international fertility clinics include LAH as standard in their IVF package for poor-prognosis patients; always confirm what is and is not included.
• Number of embryos hatched: Some clinics charge per embryo; others charge a flat fee per cycle regardless of number of embryos treated.

For patients pursuing IVF abroad, India, Thailand, the Czech Republic, Spain, and Greece offer internationally accredited fertility clinics with significantly lower overall costs and high success rates, making medical tourism for IVF an increasingly common choice for international patients.

Laser assisted hatching is one of several strategies used to improve IVF outcomes in poor-prognosis patients. It is frequently considered alongside or compared with:

• Preimplantation genetic testing for aneuploidy (PGT-A): Chromosomal screening of embryos before transfer identifies euploid (chromosomally normal) embryos, directly addressing the most common cause of IVF failure and implantation loss. PGT-A is supported by higher-quality evidence than LAH and is increasingly preferred in women ≥35 with recurrent failure.
• Blastocyst culture and transfer (Day 5): Extending culture to the blastocyst stage selects the most viable embryos through natural attrition; implantation rates per transfer are higher with blastocysts than with Day 3 cleavage-stage embryos.
• Endometrial receptivity array (ERA): Genetic testing of the endometrial lining identifies the personalised implantation window; displacing transfer by 12–24 hours to the optimal window has been shown to improve outcomes in patients with recurrent failure.
• Embryo glue (EmbryoGlue): A hyaluronan-enriched transfer medium that mimics uterine secretions; may improve implantation rates modestly and is sometimes used in conjunction with LAH.
• Endometrial scratch: A minor intrauterine intervention performed in the cycle before IVF transfer; may upregulate endometrial receptivity markers. Evidence is mixed and it remains investigational.
• Immunological treatments: Intralipid infusions, prednisolone, or G-CSF instillation for patients with suspected immunological implantation failure; used empirically in some specialist centres.
• Donor egg IVF: For women with severely diminished ovarian reserve or multiple IVF failures with own eggs, donor oocytes bypass zona and embryo quality issues entirely and achieve the highest implantation rates.

Clinical note: LAH can be combined with most of the above strategies. The approach to recurrent implantation failure should be individualised and guided by a specialist reproductive immunologist or reproductive endocrinologist with expertise in complex IVF cases.